GLP-1 Prior Authorization Denied? How to Appeal (Step-by-Step)

The letter arrives and it says denied. Your prescriber submitted the paperwork, you met with them, and you got your hopes up — and now you are holding a page that says your insurer has decided Wegovy or Zepbound is "not medically necessary." The frustration is immediate and legitimate. So is this fact: a denial at the prior authorization stage is not a final answer.

Up to 88% of patients who are denied never challenge the decision. They either abandon the medication or pivot straight to cash-pay options. That is understandable — the appeal process is opaque, time-consuming, and the forms are designed by people who do not particularly want you to succeed at them. But the appeal process exists, it is federally mandated for most plans, and success rates for patients who do appeal are meaningfully higher than most people expect.

This guide covers every stage of the process in the order you will encounter it, with the documentation that actually moves insurers and the mistakes that kill otherwise viable appeals.

Why GLP-1 prior authorizations have unusually high denial rates

Prior authorization was never designed for broadly prescribed maintenance medications. It was designed for high-cost specialty drugs, imaging procedures, and elective surgeries. GLP-1s for obesity sit in an awkward category: they cost more than $1,000 at list price per month, they are prescribed for a condition that most commercial plans have historically treated as "lifestyle" rather than "medical," and the FDA labels — which set the clinical criteria — are newer than most plans' coverage policies.

The result is a structural mismatch. In 2024, roughly 62% of GLP-1 prior authorization requests for obesity treatment were rejected on first submission. The most common stated reasons:

Step therapy (fail-first) requirements. The plan requires documented evidence that you tried cheaper alternatives — usually a structured lifestyle program, dietary counseling, and sometimes metformin — before it will approve a GLP-1. This is the single most frequent denial trigger and also the most frequently curable on appeal when the documentation exists. Our step therapy guide covers the exact documentation that satisfies most insurers.

"Not medically necessary." This language appears when the submitted documentation does not clearly establish that you meet the plan's specific criteria — typically BMI ≥ 30, or BMI ≥ 27 with at least one qualifying comorbidity (hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, dyslipidemia). Missing lab values, absent or generic physician notes, or incorrect ICD-10 codes are common culprits.

Plan exclusion. Some plans simply exclude weight-management medications outright, regardless of clinical need. This is the hardest denial to overturn because it is a coverage design decision rather than a clinical judgment — but state law challenges and the external review process can still apply. For a full picture of which payer types cover GLP-1s and which don't, see our GLP-1 insurance coverage guide.

Off-label use. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes. Using them for weight loss alone is off-label, and many plans deny for that reason even when the clinical case is clear. Wegovy (semaglutide) and Zepbound (tirzepatide) are the weight-management-specific approvals and should be prescribed when weight management is the primary indication.

Step 1: Read the denial letter carefully before doing anything else

Every denial letter issued by a commercial insurer or marketplace plan must, by federal law, state the specific reason for the denial and provide instructions for how to appeal. Read it carefully, because the reason determines your strategy.

The denial letter will typically include:

• The specific coverage criterion that was not met
• The clinical or policy rationale (often citing the plan's medical necessity guidelines)
• The appeal deadline (critical — do not miss this)
• The address, fax number, or portal for submitting your appeal
• Whether the reviewer is internal or an external contractor

Request your complete internal claim file. You have the right to obtain all documentation the insurer used to make its decision. Call member services and ask for it specifically. This sometimes surfaces administrative errors — a miskeyed ICD-10 code, a missing lab result the prescriber faxed that did not attach correctly, or a step-therapy checklist that was completed but not transmitted.

Do this before you write a single word of your appeal. The fix is sometimes cleaner than you think.

Step 2: Build your documentation package

The appeal stands or falls on documentation. A well-prepared insurer's reviewer will look for a direct and specific answer to every reason listed in the denial letter. Generic appeals — "my doctor says this medication is necessary" — fail because they do not address the specific criterion the insurer flagged.

The foundation of every GLP-1 appeal is a Letter of Medical Necessity from your prescribing physician. This is different from a simple prescription note. An effective letter includes:

• Your full diagnosis with ICD-10 codes (E66.9 for obesity, E11.9 for type 2 diabetes, G47.33 for obstructive sleep apnea, I10 for hypertension, and others as applicable)
• Your current BMI and weight trend over time, taken from documented office visits — not self-reported
• A list of qualifying comorbidities with supporting lab values (HbA1c, fasting glucose, lipid panels, blood pressure readings)
• A documented history of previous weight-loss interventions: programs attended, medications tried, dates, doses, duration, and why each was insufficient or caused adverse effects
• A clinical explanation of why a GLP-1 agonist is medically appropriate for your specific situation
• Reference to published clinical evidence — the STEP 1-4 trials for semaglutide or the SURMOUNT-1 and SURMOUNT-2 trials for tirzepatide are directly relevant
• The specific drug being requested and its FDA-approved indication

A generic checkbox form from your prescriber's office is not this letter. You may need to specifically ask your prescriber to write a detailed narrative letter, and it helps to give them the denial reason in writing so they can address it directly.

Supporting documents to attach:

• Copies of medical records showing prior weight management visits
• Lab results within the past 6–12 months
• Documentation of lifestyle programs attended (receipts, membership records, coach notes, app exports)
• Any documentation of prior medications attempted (prescription history from your pharmacy is useful here)
• Printed clinical guidelines from professional bodies — the American Association of Clinical Endocrinology (AACE), Obesity Medicine Association (OMA), and the American Heart Association have all published position statements on GLP-1 use for obesity and cardiovascular risk

Step 3: Write your appeal letter

Your appeal letter accompanies the documentation package. Its job is to connect the evidence to the insurer's specific denial rationale and make the reviewer's job as easy as possible.

A working structure:

1. Opening: State your name, member ID, policy number, claim number, and the date of the denial you are appealing.
2. State your request: "I am requesting reconsideration of the denial of [specific medication, dose, duration]."
3. Address the denial reason directly: Quote the denial reason back and explain specifically why it is incorrect or why the documentation now addresses it. Do not argue in the abstract — respond to what they actually said.
4. Medical necessity argument: Summarize your clinical history, comorbidities, and failed prior treatments. Reference the attached Letter of Medical Necessity and specific documents.
5. Clinical evidence: Note the FDA approval for your specific indication and cite the clinical trials supporting efficacy and cardiovascular benefit. For Wegovy, the SELECT trial (2023) demonstrated a 20% reduction in major cardiovascular events in patients with established cardiovascular disease and obesity — this is relevant if you have a cardiac history.
6. Closing request: Ask for a prompt review and state your preferred contact information.

Language that tends to be effective: frame the request as medically necessary treatment for a chronic condition, not as a weight-loss intervention. Obesity is classified as a chronic disease by the American Medical Association and the World Health Organization. Insurers' own medical necessity guidelines typically align with FDA labeling criteria — and if your clinical profile matches those criteria, say so explicitly and cite the criteria.

Language to avoid: appeals that frame the request in terms of how the patient "deserves" coverage, how other patients are getting the medication, or that make cost arguments without clinical grounding rarely succeed on their own.

Step 4: Submit and track your appeal

Submit through the method specified in your denial letter — most large insurers now have online member portals. If you fax or mail, send via certified mail and keep the tracking record. Document every submission with a date stamp, reference number, and the name of anyone you spoke with.

Standard timelines under federal rules:

• Pre-service appeals (for medications not yet received): insurer must decide within 30 days
• Post-service appeals (for expenses already paid): 60 days
• Urgent/expedited appeals (when standard timing would seriously jeopardize health): 72 hours

Your prescriber must certify urgency for the expedited track. If you are already on the medication and risk interrupting treatment, that clinical argument is worth making in writing.

Step 5: Request a peer-to-peer review

If the first internal appeal is denied — or sometimes in parallel with it — your prescribing physician can request a peer-to-peer review. This is a direct phone call between your prescriber and the insurer's reviewing physician or medical director.

You cannot request this yourself. Your prescriber must initiate it. The insurer's reviewer is typically a physician in the same or related specialty, and the conversation is clinical rather than administrative.

Peer-to-peer reviews matter because they convert a paper-based review into a direct clinical argument. A prescribing physician who knows your case history, your failed prior treatments, and can speak to your comorbidities in real time has a meaningfully different kind of influence than a documentation package. Patients whose doctors pursue peer-to-peer calls after an initial denial report approval at materially higher rates than those who rely only on written submissions.

Ask your prescriber specifically: "Will you request a peer-to-peer review if my appeal is denied?" Not all practices routinely offer this, and it requires time from your provider — but it is a standard part of the process.

Step 6: Escalate to independent external review

If the insurer's internal process exhausts without approval, you have the right under the Affordable Care Act to an independent external review. This is a review by a third party not affiliated with your insurer. Under the ACA, the external reviewer's decision is binding — the insurer must honor a favorable outcome.

External review reversal rates for GLP-1 and obesity medication denials are not separately published, but across all medical denials, approximately 40% of external reviews overturn the insurer's decision. That is a meaningful number for a process many patients never reach.

To request external review:

1. Exhaust all internal appeal stages first (some states allow you to bypass this if the insurer delays)
2. Request external review within 60 days of your final internal denial (state laws vary — some allow longer)
3. Your insurer must provide information on how to initiate external review in their final denial letter
4. The federal external review process is administered through your state insurance department for fully-insured plans; self-funded employer plans use the federal external review process through HHS

If your plan is self-funded (many large employer plans are), the process differs slightly — your plan administrator can direct you to the correct process.

Step 7: State insurance commissioner complaint

If the external review does not go your way, or if you believe your insurer is improperly applying its own coverage criteria, you can file a complaint with your state's insurance commissioner. This is a slower process — 90 days or more — but it creates a formal regulatory record and sometimes prompts plan reconsideration independently of the appeal process.

This step is most relevant when a plan's stated coverage criteria appear to conflict with FDA labeling or ACA non-discrimination provisions.

What actually works: insights from patients who have navigated this

Across accounts from patients who have successfully appealed GLP-1 prior authorization denials, several patterns recur:

Document the step-therapy history meticulously, with dates. The most common successful appeals are those where a patient had genuinely tried prior treatments — Weight Watchers, Noom, a medically supervised diet program, prior medications — but had those attempts documented in their medical record and their appeal letter. "I tried everything" is not documentation. A list of specific programs, dates enrolled, duration, and outcome is.

Comorbidities are the clinical lever. Patients who are approved on appeal often have a clearly documented comorbidity — cardiovascular disease, type 2 diabetes, sleep apnea, or hypertension — that connects the GLP-1 to a specific FDA-approved indication or clinical guideline beyond obesity alone. If you have a cardiovascular history and are requesting semaglutide, the SELECT trial data directly supports medical necessity.

The first denial is often administrative, not clinical. Many first-level denials result from missing documentation, not a judgment that you do not medically qualify. Correcting the documentation and resubmitting resolves a meaningful share of cases without requiring a full appeal fight.

One r/Ozempic user who had her BMI fall exactly at the 30 threshold described being denied twice before being approved: "I finally was approved for Ozempic in July after advocating for myself for six months." The advocacy was persistent resubmission with escalating documentation at each stage — not a single letter.

The insurance-first telehealth option

Three telehealth platforms specifically orient their model around helping patients get GLP-1s covered through commercial insurance:

Calibrate requires that you have insurance coverage and specifically selects patients it can get approved. Their clinical team handles the full PA process and appeal sequence. This is their core differentiator — the platform is not viable if your insurance will not cover the drug.

Form Health takes a similar approach: physician-led care team, full PA management, and appeals handled by their staff. The focus is on patients with commercial insurance coverage.

Mochi Health is more flexible — it serves both insurance-covered and cash-pay patients. Their clinical team submits prior authorizations and will pursue appeals, but they also have a self-pay track if insurance fails.

Using one of these platforms instead of working through a solo prescriber does not guarantee approval, but their clinical documentation is purpose-built for insurer criteria in ways that a general practice note is often not. If the appeal process feels unmanageable to navigate alone, these platforms offer a structured alternative. For guidance on obtaining a prescription in the first place, see our how to get a GLP-1 prescription guide.

Bridge options while you wait

The appeal process takes time. A standard internal appeal can take 30 days, an external review up to 60 days, and a state commissioner complaint longer still. If you were already taking the medication and face an interruption, or if you need to start treatment while appealing, there are cash-pay options that do not require insurance approval.

NovoCare Pharmacy charges $199/month for the first two starter-dose fills of Wegovy and $349/month flat for all doses thereafter (as of May 2026). There is no insurance requirement. Pens ship direct.

LillyDirect charges $299–$449/month for Zepbound depending on dose tier (as of May 2026). This applies to both vials and KwikPens. Again, no insurance required.

These are not cheap by absolute terms, but they are dramatically less than the $1,349 retail pharmacy price and allow you to maintain treatment continuity while the appeal plays out. See our full comparison of cash-pay options for the complete picture.

Mistakes that kill otherwise viable appeals

Missing the deadline. The 180-day window is standard but not universal. Some plans set a 60-day window. Read the denial letter and treat the deadline as a hard constraint.

Submitting a generic appeal. An appeal that does not directly address the specific denial reason will be denied again, faster. Every sentence of your appeal should trace back to what the insurer said.

Relying on your prescriber to manage the process without explicit direction. Many prescribers submit PA requests routinely but do not automatically escalate to a formal written appeal or request a peer-to-peer review. Ask explicitly and in writing.

Not requesting the internal claim file first. Without it, you may be writing an appeal to fix a problem that was already fixed on resubmission — or missing the actual error that caused the denial.

Appealing before the documentation is complete. A rushed appeal with incomplete documentation is often worse than a deliberate appeal filed two weeks later with a complete package. The appeal does not toll the treatment clock — you can still bridge on cash-pay while building the proper file.

Framing the appeal as a cost argument rather than a clinical one. "This medication will save money in the long run" is not a medical necessity argument. Your insurer's reviewer is evaluating clinical criteria, not budget projections.

Realistic timelines

Here is a realistic map of the full appeal sequence from denial to resolution:

From first denial to external review outcome, a contested case commonly takes three to four months. That is not fast. It is, however, reversible — which the cash-pay price tag is not.